Glimepirid Zentiva

Glimepirid Zentiva is a prescription oral medication that contains the active ingredient glimepiride. It is a second‑generation sulfonylurea classified as an antidiabetic, oral hypoglycemic drug. The product is marketed in the European Union and is intended for adult patients with type 2 diabetes mellitus. Specific strength and dosage form are not disclosed in the available data.

Glimepirid Zentiva is indicated for the management of blood glucose levels in adults with type 2 diabetes mellitus, typically as part of a comprehensive treatment plan that includes diet and exercise.

- Used when diet, exercise, and lifestyle changes alone do not achieve target glycaemic control. - May be combined with metformin or other oral antidiabetic agents. - Helps reduce fasting and post‑prandial blood glucose concentrations. - Often prescribed after other first‑line therapies have been evaluated. - Can be part of a step‑wise intensification strategy for progressive diabetes management.

Glimepirid Zentiva may cause a range of side effects, most of which are mild and transient, while serious reactions are less common but require prompt medical attention.

Common: - Mild hypoglycaemia, especially if meals are missed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity.

Serious: - Severe hypoglycaemia with confusion, seizures, or loss of consciousness. - Allergic reactions such as rash, itching, or swelling of the face and throat.

Before starting Glimepirid Zentiva, patients should consider several safety factors to minimise risks and optimise therapeutic outcomes.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Review history of cardiovascular disease, since sulfonylureas can influence cardiac metabolism. - Monitor blood glucose regularly to detect hypoglycaemia early. - Use caution in elderly patients who may be more sensitive to insulin‑secretagogue effects. - Discuss any pregnancy or breastfeeding plans with a healthcare professional. - Avoid abrupt discontinuation without medical guidance to prevent rebound hyperglycaemia.

Glimepirid Zentiva can interact with several drug classes, altering its efficacy or increasing the risk of adverse events.

Avoid: - Concurrent use of other sulfonylureas or insulin, which may cause severe hypoglycaemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - High‑dose salicylates, which may potentiate hypoglycaemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycaemia symptoms. - Thiazide diuretics, as they may affect glucose tolerance. - ACE inhibitors or ARBs, requiring monitoring of renal function and electrolytes.